Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Takeda Revving Up Efforts to Retool Japan Sales System as It Prepares for “New Normal” Post COVID-19
May 18, 2020
-
REGULATORY Japan’s First Humira Biosimilar Could Hit Market as Early as November
May 15, 2020
-
REGULATORY Japan Poised to Quickly Approve Futhan, Actemra, Ivermectin for COVID-19 If Effective: Abe
May 15, 2020
-
REGULATORY Chuikyo Members Frown on Zolgensma’s Sakigake Premium; Topic Up for 2022 Pricing Debate
May 14, 2020
-
BUSINESS Eisai Resurrects Eritoran as Potential COVID-19 Treatment, Eyes Trial Launch Next Month
May 14, 2020
-
BUSINESS Takeda Exec Says Plasma Alliance Could Start Clinical Trial for Unbranded Therapy in July
May 14, 2020
-
REGULATORY Daiichi Sankyo’s Enhertu, Novartis’ Beovu, Novo’s Ozempic OK’ed for Listing on May 20
May 13, 2020
-
REGULATORY Japan Regulators Upped Zolgensma Price after Novartis Complaints: Chuikyo Paper
May 13, 2020
-
REGULATORY Zolgensma to Get Japan’s Highest List Price 167 Million Yen, but Peak Sales Put at Just 4 Billion Yen
May 12, 2020
-
BUSINESS Amgen Boosting Repatha Supply System to Gear Up for Praluent Switches
May 11, 2020
-
BUSINESS Praluent Barred in Japan after Top Court Nixes Sanofi’s Patent Claim
May 8, 2020
-
REGULATORY Japan Approves Remdesivir as First Drug for COVID-19
May 8, 2020
-
REGULATORY Japan to Test Ivermectin for COVID-19: Prime Minister
May 7, 2020
-
BUSINESS Gilead Files Remdesivir for COVID-19 in Japan
May 4, 2020
-
REGULATORY Japan Likely to Take FDA’s Anticipated EUA as Cue for “Special” Remdesivir OK
May 1, 2020
-
BUSINESS Sanofi Japan to Ensure Drug Supplies, Employees’ Safety at the Same Time in COVID-19 Crisis: Chief
April 30, 2020
-
REGULATORY Japan Might Approve Gilead’s Remdesivir for COVID-19 in May
April 28, 2020
-
BUSINESS Novartis Japan Scraps Sales Offices to Boost Efficiency of Rep Activities
April 27, 2020
-
REGULATORY Japan Moving to Thwart Foreign Takeover of Drug, Medical Devices Makers
April 24, 2020
-
BUSINESS Gene Techno CEO Eyes Lucentis Biosimilar Launch in November 2021, Expects Share of “At Least 30%”
April 23, 2020
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…